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Heart Failure in Women
A Need for Prospective Data
Eileen M. Hsich, MD,*† Ileana L. Piña, MD†
Cleveland, Ohio
Heart failure affects 5 million Americans, and nearly 50% of these are women. Sex differences have been noted re-
garding the underlying etiology, pathophysiology, and prognosis. Women are less likely to have coronary artery dis-
ease and more likely than men to have hypertension and valvular disease as the underlying etiology. They often
present at an older age with better systolic function than men. For both sexes, there is significant morbidity, but age-
adjusted data reveal that women have a better survival. Despite these known sex differences, medical management
recommendations are the same for women and men, because prospective sex-specific clinical trials have not been
performed. However, our review raises some concerns that women might respond differently to therapy. (J Am Coll
Cardiol 2009;54:491–8) © 2009 by the American College of Cardiology Foundation






























Aore women die every year of cardiovascular disease (CVD)
han of breast or uterine cancer. Although nearly 50% of the
emale CVD mortality is due to coronary heart disease,
eart failure (HF) contributes 35% of the total female CVD
ortality (1). Despite this fact, HF in women remains a
oorly recognized and poorly understood syndrome and has
ot received the same public awareness as coronary heart
isease. The objective of this work is to review sex differ-
nces in epidemiology, etiology, diagnosis, and prognostic
esting and discuss sex-specific results from the landmark
F trials that have shaped our current medical practice. In
ddition, to guide practitioners when caring for women with
F, this review will offer practical suggestions. For sex
ifferences in HF pathophysiology, we refer readers to the
xcellent review by Konhilas and Leinwand (2).
pidemiology/Prognosis/Etiology
eart failure affects 5.3 million Americans, and nearly 50%
f these are women (1). The prevalence of HF increases
ith age for both sexes, with more women than men having
F after 79 years of age (1). Women with acute decom-
ensated HF tend to have HF with preserved left ventricular
LV) function almost twice as often as men (3,4), and those
ith impaired LV systolic function tend to present with a
igher left ventricular ejection fraction (LVEF) when
ompared with men (3). Additionally, comorbidities are
ommon. Women with HF tend to have more hyperten-
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009, accepted February 9, 2009.ion compared with men, who have more smoking and
oronary artery disease (CAD) (5). Thyroid disease is
ore frequent in women with acute decompensated HF,
hereas chronic obstructive lung disease, peripheral vas-
ular disease, and renal insufficiency are more common in
en (3,4).
Age-adjusted HF incidence is higher in men than in
omen, yet the prevalence is similar, because men with HF
ave shorter survival than women (6,7). The incidence of
F from 1979 to 2000 rose 8% (95% confidence interval
CI]: 5% to 23%) in women and 3% (95% CI: 11% to
0%) in men according to the Olmsted County data (6),
hich validated 4,537 cases of new onset HF. Similarly, the
ramingham investigators also reported an increase in the
ncidence of HF for both women and men between 1980
nd 1999 (7). During those time periods, age-adjusted,
-year mortality improved for both sexes (6,7).
There is significant morbidity associated with HF, and
omen have been shown to have a lower quality of life than
en, with more functional capacity impairment (8), more
F hospital stays (1,3,8), and depression (9). Nonetheless,
urvival is better for women (6,7). The cause for sex differ-
nces in mortality remains unknown, but 2 leading hypoth-
ses are differences in systolic function and in etiology.
omen are more likely than men to have HF with
reserved LV systolic function, which was believed to have
better prognosis than impaired LV function. However, 2
ecent observational studies showed a similar mortality rate
or HF patients with preserved or impaired systolic function
10,11). Women also have less ischemic cardiomyopathy,
nd survival might be related to sex differences in etiology
12). Although the CHARM (Candesartan in Heart failure
ssessment of Reduction in Mortality and morbidity) study
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HF in Women August 4, 2009:491–8explained by LV systolic function
or by etiology, there was a worse
prognosis for both women and
men with ischemic cardiomyop-
athy (Fig. 1) (5).
Tests used for survival predic-
tion might require sex-specific in-
terpretation. For example, brain
natriuretic peptide 500 pg/ml
might be a stronger predictor of
death in women with HF than in
men (13). Cardiopulmonary exer-
cise testing, often used to deter-
mine optimal timing for listing for
heart transplantation, seems to be
an excellent predictor of death in
both women and men (14), but for
any given peak oxygen consump-
tion women have a better survival
(14,15). However, women with
an ischemic cardiomyopathy
have a worse prognosis com-
pared with those women with a
nonischemic cardiomyopathy
for any given peak oxygen con-
sumption (Fig. 2) (14).
Heart failure is associated with
any risk factors with some sex differences. Women are more







CAD  coronary artery
disease
CI  confidence interval
CVD  cardiovascular
disease
HF  heart failure
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LV  left ventricular
LVEF  left ventricular
ejection fraction
NIH  National Institutes
of Health




RR  relative risk
Figure 1 Kaplan-Meier Curves for All-Cause Mortality in the CH
Kaplan-Meier curves for all-cause mortality in the CHARM (Candesartan in Heart fa
with heart failure on the basis of the presence or absence of an ischemic cardiomnderlying etiology for HF and less likely to have CAD (3–5).
lthough CAD is less common, it is such a significant risk
actor that women are more likely to develop HF with CAD
han with hypertension. For example, in the NHANES
National Health and Nutrition Examination Survey) I sur-
ey—which included 8,098 women without HF—27% had
ypertension and only 3% had CAD, but the relative risk (RR)
f developing HF for women was significantly higher if they
Study
ssessment of Reduction in Mortality and morbidity) study for women and men
y. Adapted from O’Meara et al. (5).
Figure 2 Adjusted Predicted Mortality
Adjusted predicted mortality in women with heart failure and impaired sys-
tolic function on the basis of peak oxygen consumption (VO2) and the pres-
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August 4, 2009:491–8 HF in Womenad CAD (RR: 8.16; 95% CI: 6.79 to 9.8; p  0.001) than if
hey had hypertension (RR: 1.51; 95% CI: 1.29 to 1.77; p 
.001) (16). Diabetes mellitus is common in both sexes (i.e.,
4%) (3) and is one of the strongest additional risk factors for
he development of HF in women with CAD (17). Other
auses of HF include cardiac toxicity from chemotherapeutic
gents used to treat breast malignancy and peripartum cardio-
yopathy (PPCM).
PCM
PCM is the development of HF with impaired systolic
unction in the last month of pregnancy or within 5 months
ost-partum with no pre-existing cardiac disease or identi-
able cause (18). The incidence varies on the basis of the
opulation studied, with an estimated occurrence in 1 of
,000 pregnancies in the U.S. (18). The etiology remains
nknown, but potential causes include myocarditis, abnor-
al immune response to pregnancy, increased myocyte
poptosis, genetic predisposition, and proteolytic cleavage of
rolactin during oxidative stress. Risk factors include ad-
anced maternal age, African descent, high parity, twin
regnancy, usage of tocolytics, and poverty (19). Approxi-
ately one-half of PPCM patients recover normal systolic
unction within 6 months (20). Another 20% deteriorate
nd either die or require heart transplantation (21). The
egree of LV systolic dysfunction at presentation might
redict recovery. In 1 study involving 33 patients with
PCM, those who recovered LV systolic function had a
igher LVEF at presentation (LVEF 35 4% vs. 25 4%,
 0.001) (22). In another study involving 98 patients from
aiti with PPCM, a similar finding was noted, with
ecovery more likely in patients with less severe systolic
ysfunction (LVEF 28%, 95% CI: 15% to 41% vs. LVEF
3%, 95% CI: 11% to 35%, p  0.001) (23). There are
imited data regarding the risk of subsequent pregnancies.
ne retrospective study noted that the average LVEF after
ubsequent pregnancy was reduced both in patients who had
ecovered systolic function before pregnancy (n  28;
VEF 56  7% reduced to 49  10%, p  0.002) and in
hose with persistent LV systolic dysfunction (n  16;
VEF 36  9% reduced to 32  11%, p  0.08). All 3
atients who died in this series had LV systolic dysfunction
efore the subsequent pregnancy (24). Preliminary data
nvolving animal research and 12 PPCM patients suggest
hat bromocriptine, which inhibits prolactin secretion,
ight help prevent death and deterioration of LV function
pon subsequent pregnancies by preventing the formation
f a 16-kDA prolactin fragment. An imbalance of oxidative
tress during pregnancy or in the peripartum period can
ause prolactin to be cleaved by cathepsin D into a 16-kDA
rolactin fragment, which can destroy the cardiac microvas-
ulature and lead to LV cavity dilation and systolic dysfunc-
ion (25). The 16-kDA prolactin fragment induces endo-
helial apoptosis (26), inhibits vascular endothelial growth
actor-induced proliferation of endothelial cells, and impairsitric oxide-mediated vasorelaxation (27). Although this is
otentially an exciting breakthrough in the pathophysiology
f PPCM, the data are preliminary, and the usage of
romocriptine in the post-partum period to suppresses
actation has been associated with increased incidence of
ardiovascular events, hypertension, and thrombus forma-
ion (19). Therefore, it is reasonable to await the results of
arger studies with usage of bromocriptine and to counsel
omen who have a diagnosis of PPCM about subsequent
regnancies and the need to remove angiotensin-converting
nzyme inhibitor (ACEI)/angiotensin receptor blocker
ARB) therapy should a new pregnancy occur.
iagnosis
he diagnosis of HF is a clinical diagnosis based on a
onstellation of symptoms and signs (28). According to the
OLVD (Studies Of Left Ventricular Dysfunction) data-
ase, women with impaired systolic LV function are more
ikely than men to have dependent edema, jugular venous
istension, and an S3 gallop (29). In contrast, according to
DHERE (Acute Decompensated Heart Failure National
egistry) (impaired and preserved systolic function), there
ere no clinically important differences in the frequency of
F symptoms/signs between women (n 54,674) and men
n  50,713) (3). This apparent difference in symptom
bservation might be related to the fact that the ADHERE
egistry was derived from patients hospitalized for acute
ecompensation compared with most clinical trials where
atients present with chronic symptoms.
Diagnostic tests to assess LV function are frequently used
o further classify HF patients into those with impaired or
reserved LV systolic function and to assess for other
tructural heart disease. From both the Framingham and the
lmstead County databases, more women than men have
F with preserved LV function (30,31) as depicted in
igure 3. Coronary angiography might determine who has
Figure 3 LVEF
Left ventricular ejection fraction (LVEF) in women and men with congestive
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HF in Women August 4, 2009:491–8n ischemic cardiomyopathy. Brain natriuretic peptide, a
iomarker, is being used more frequently to identify patients
ith symptoms of HF and to risk stratify. However,
normal” brain natriuretic peptide values are higher in
omen versus men (32). More studies are needed that will
ddress sex differences in biomarker levels and strategies to
ntervene on outcomes. Sufficient women need to be en-
olled so that analyses can be carried out by sex.
herapy
ost clinical trials have not planned to prospectively ana-
yze the female cohort or enroll a certain percentage of
omen. One exception is BEST (Beta-Blocker Evaluation
emale Participants in Chronic Heart Failure TrialsTable 1 Female Participants in Chronic Heart Failure Trials
Study (Ref #) % Women Number of Women LVEF
A-HeFT (47) 40 420 35%
BEST (12) 22 593 35%
CARE-HF (55) 26 215 35%
CHARM-low LVEF (37) 26 1,188 40%
CIBIS II (41) 19 515 35%
COMPANION (52) 32 493 35%
CONSENSUS (63) 30 75 Any
COPERNICUS (40) 20 469 25%
DIG (48) 22 1,520 45%
ELITE-II (61) 31 966 40%
EPHESUS (45) 29 1,918 40%
MADIT II (55) 16 192 30%
MERIT-HF (42) 23 898 40%
RALES (43) 27 446 35%
SCD HeFT (54) 23 588 35%
SOLVD prevention (29) 13 548 35%
SOLVD treatment (29) 20 514 35%
U.S. Carvedilol (40) 23 256 35%
Val-HeFT (38) 20 1,003 40%
V-HeFT I (45) 0 0 45%
V-HeFT II (46) 0 0 45%
VEF  left ventricular ejection fraction.
isk of Mortality and/or Hospital Stay in Female HF PatientsTable 2 Risk of Mortality and/or Hospital Stay in Female HF P
Study (Ref #) End Point*
U.S. Carvedilol HF Study (39) Mortality
A-HeFT (47) Mortality
ACEI meta-analysis (35) Mortality
ACEI meta-analysis (35) Mortality or HF hospital stay
BEST (12) Mortality
CIBIS II (41) Mortality
Val-HeFT† Mortality
Val-HeFT† HF hospital stays
ELITE II (61) Mortality
SCD-HeFT (amiodarone) (54) Mortality
SCD-HeFT (ICD) (54) Mortality
CARE-HF (53) Mortality  hospital stayEnd point for sex-specific results and not necessarily primary end point of trial. †Unpublished data provi
HF  heart failure; HR  hazard ratio; OR  odds ratio; RH  relative hazard.f Survival Trial), which stratified patients by sex (12).
onsequently, current guidelines for HF therapy (28,33) are
ot sex specific due to under-representation of women
Table 1) and lack of sex-specific, prospective, randomized
linical trials. The summaries that follow refer mostly to HF
ith impaired systolic function and should be interpreted
ith caution, because they have been derived from retro-
pective studies or post hoc analyses.
CEI. ACEIs are currently recommended for all patients
ith HF and impaired systolic function, because of the
nown morbidity and mortality benefits (28,34). Unfortu-
ately, few women participated in these landmark HF
linical trials, and therefore the benefits in women remain
nclear. A meta-analysis consisting of 30 ACEI studies
nvolving a total of 1,587 women with HF demonstrated a
rend toward improved survival in the group taking ACEIs
ompared with those not taking the drug (13.4% vs. 20.1%)
nd a favorable trend in the combined end point of survival
nd hospital stay in the group of women taking an ACEI
20.2% vs. 29.5%) (35). Another meta-analysis involving
,373 women revealed similar trends and noted that women
ho were symptomatic benefited more than those who were
symptomatic (36). However, both meta-analyses had wide
Is that crossed 1.0, raising some uncertainty about the
ctual benefit (Table 2).
RBs. Angiotensin receptor blockers are used in ACEI-
ntolerant HF patients or in addition to an ACEI (28).
ex-specific data for ARBs are limited, but candesartan and
alsartan seem beneficial in women. Pooled data from the
HARM-Alternative (ARB for patients intolerant of
CEI) and CHARM-Added trials (ARB added to an
CEI) that included 1,188 women, New York Heart
ssociation (NYHA) functional class II to IV with LVEF
40%, showed that candesartan reduced the combined end
oint of cardiovascular death or HF hospital stay in women
37). In the Val-HeFT (Valsartan Heart Failure Trial),
hich included 1,003 women with NYHA functional class
ts
HR, RH, or OR (95% CI)
Women Men
HR: 0.23 (0.07–0.69) HR: 0.41 (0.22–0.80)
HR: 0.33 (0.16–0.71) HR: 0.79 (0.46–1.35)
OR: 0.79 (0.59–1.06) OR: 0.76 (0.65–0.88)
OR: 0.78 (0.59–1.04) OR: 0.63 (0.55–0.73)
HR: 0.82 (0.60–1.13) HR: 0.85 (0.73–0.99)
RH: 0.53 (0.42–0.67) RH: 0.37 (0.19–0.69)
HR: 0.93 (0.68–1.27) HR: 1.04 (0.90–1.19)
HR: 0.74 (0.55–0.98) HR: 0.73 (0.62–0.86)
HR: 1.14 HR: 1.12
HR: 1.17 (0.72–1.90) HR: 1.04 (0.83–1.30)
HR: 0.96 (0.58–1.61) HR: 0.73 (0.57–0.93)
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August 4, 2009:491–8 HF in WomenI to IV and LVEF 40%, valsartan when compared with
lacebo did not significantly reduce mortality in women but
id reduce HF hospital stay (hazard ratio [HR]: 0.74, 95%
I: 0.55 to 0.98) and first morbid event (HR: 0.79, 95% CI:
.63 to 0.99) (I. Anand, personal communication, April 22,
008), which was defined as cardiac arrest, HF hospital stay,
r administration of intravenous inotrope/vasodilator ther-
py (Table 2) (38).
eta-blockers. Three beta-blockers are proven in multi-
enter, prospective, randomized studies to reduce mortality
nd morbidity in HF patients with impaired systolic func-
ion: carvedilol, bisoprolol, and metoprolol succinate. Post
oc analyses suggest that these agents, when added to an
CEI, are beneficial in women with HF despite the
elatively small number of female participants in each study.
Carvedilol is a nonselective beta-adrenergic antagonist
ith alpha-blocking and antioxidant properties. Carvedilol
mproved survival in the 256 women participating in the
.S. Carvedilol Heart Failure Study of HF patients with
oderate symptoms and LVEF 35% (HR: 0.23, 95% CI:
.07 to 0.69) (39), although this was not a mortality trial. In
he COPERNICUS (Carvedilol Prospective Randomized
umulative Survival Study) study, carvedilol reduced the
ombined end point of death or hospital stay in the 469
omen studied with LVEF 25% and severe HF symp-
oms. Most of this benefit was due to a reduction in hospital
tays, because the mortality data had a wide CI and the HR
rossed 1.0 (40).
Bisoprolol and metoprolol succinate are beta1-selective
drenergic antagonists. In the European CIBIS II (Cardiac
nsufficiency Bisoprolol Study), bisoprolol improved survival
n the 515 women studied who were NYHA functional class
II or IV and had LVEF 35% (relative hazard: 0.37, 95%
I: 0.19 to 0.69) (41). In the MERIT-HF (Metoprolol
xtended-Release Randomized Intervention Trial in Heart
ailure) trial, metoprolol succinate had no survival benefit
or women (6.9% vs. 7.5%, p  NS) but did reduce HF
ospital stay by 42% (p  0.021) in the 898 women
tudied with LVEF 40% who were NYHA functional
lass II to IV. This effect was even more dramatic with a
2% reduction in HF hospital stays (0.54 vs. 0.15; p 
.0004) in the subgroup of women (n  183 patients)
ith LVEF 25% (42).
ldosterone antagonists. Aldosterone antagonists are one
f the few medications deemed by subgroup post hoc
nalysis to have a total mortality benefit for women with
ystolic HF on the basis of both the RALES (Randomized
ldactone Evaluation Study) and EPHESUS (Epleronone
ost-Acute Myocardial Infarction Heart Failure Efficacy
nd Survival Study) trials (43,44). The RALES trial included
46 women and studied the effects of spironolactone in
schemic and nonischemic cardiomyopathy patients with
YHA functional class III to IV and LVEF 35% (43). The
PHESUS trial included 1,918 women participants and
tudied the effects of eplerenone after an acute myocardial
nfarction in patients with LVEF 40% (44). Hydralazine/isosorbide dinitrate. The combination of
ydralazine and isosorbide dinitrate has been commonly
sed in HF patients who cannot tolerate an ACEI or ARB.
he original data supporting the use of this combination by
emonstrating a survival benefit included only men (45,46).
n fact there remain no published data for women using
ydralazine and isosorbide dinitrate as a substitute for an
CEI or ARB. Added to ACEI/ARB and beta-blockers,
his combination has been studied in the A-HeFT (African-
merican Heart Failure Trial), which included 420 women
articipants who were NYHA functional class III to IV.
he trial was prematurely stopped because of the significant
urvival benefits that were noted for both women (HR: 0.33,
5% CI: 0.16 to 0.71, p  0.003) and men (HR: 0.79, 95%
I: 0.46 to 1.35, p  0.385) with no significant treatment
nteraction by sex. There were also fewer first hospital stays
or HF in both women (HR: 0.62, 95% CI: 0.41 to 0.96,
 0.03) and men (HR: 0.60, 95% CI: 0.42 to 0.89, p 
.005) (47).
igoxin. Digoxin reduces HF hospital stay but has no
eneficial effect on survival (48).
In women with impaired systolic function, there was an
nitial concern of increased mortality (adjusted HR: 1.23,
5% CI: 1.02 to 1.47) that was not observed in men
adjusted HR: 0.93, 95% CI: 0.85 to 1.02) on the basis of a
ost hoc subgroup analysis of the Digitalis Investigation
roup trial (49). The increased mortality was presumed to
e due to digoxin toxicity, because the risk of death
ncreased at higher serum drug levels. Drug levels between
.2 and 2.0 ng/ml were associated with increased mortality
HR: 1.33, 95% CI: 1.001 to 1.76, p  0.049), and levels
etween 0.5 and 0.9 ng/ml were considered safe for both
omen and men (HR: 0.8) on the basis of a retrospective
nalysis (50).
ntiplatelet agents and anticoagulation. In a retrospec-
ive analysis of the SOLVD trial, women with HF had an
ncreased risk of thromboembolic events compared with
en. Although women had more thromoboembolic events
mostly pulmonary embolic events) they were also less likely
han men to be taking antiplatelet agents or anticoagulation
herapy. In fact, the use of an antiplatelet agent in women
ignificantly reduced the likelihood of this complication
51). Further information regarding this topic might be
rovided by the ongoing WARCEF (Warfarin Versus
spirin in Reduced Ejection Fraction) trial.
ardiac resynchronization therapy (CRT). CRT is rec-
mmended for HF patients with LVEF 35%, NYHA
unctional class III to IV symptoms in spite of optimal
edical therapy, and a wide QRS (QRS120 ms), on the
asis of large, prospective, randomized multicenter studies
hat demonstrated improvement in symptoms, functional
apacity, and mortality (52,53). Although few studies have
eported sex-specific data, it seems that CRT is beneficial
or both women and men. In the COMPANION (Com-
arison of Medical Therapy, Pacing, and Defibrillation in
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HF in Women August 4, 2009:491–8ith CRT had a greater reduction in the combined end point
f total mortality or hospital stay for any cause compared with
omen given just medical therapy (52). A retrospective anal-
sis of the CARE-HF (Cardiac Resynchronization–Heart
ailure) data—a study that included 215 women—suggested
hat CRT was preferable to medical therapy alone in women
or the combined end point of total mortality and hospital stay
or major cardiovascular events (Table 2). All patients were
unctional NYHA functional class III or IV, had LVEF
35%, LV end-diastolic diameter 30 mm as indexed for
eight, and QRS 120 ms with evidence of dyssynchrony if
RS was 120 to 149 ms (53).
mplantable cardioverter-defibrillator (ICD). The rec-
mmendations for an ICD to prevent sudden death are
ased on many multicenter studies, but few have provided
ex-specific data (52,54). Unfortunately, the limited post
oc analyses available for women with an ICD do not clearly
emonstrate a mortality benefit (52,54,55). In the SCD-
eFT (Sudden Cardiac Death in Heart Failure Trial),
hich included 588 women in NYHA functional class II to
II with LVEF 35% (ischemic and nonischemic cardio-
yopathy), the benefits of an ICD were not clear, although
he trial was not powered to detect sex differences (women
R: 0.96, 95% CI: 0.58 to 1.61). In the MADIT (Multi-
enter Automatic Defibrillator Implantation Trial) II,
hich included 119 women with an ischemic cardiomyop-
thy LVEF 30%, there was a nonsignificant trend toward
ower mortality in women with an ICD (adjusted HR: 0.57,
 0.132), suggesting that this subgroup (ischemic cardio-
yopathy) might benefit. However, this analysis was lim-
ted by too few women participants (55).
entricular assist device (VAD). VADs are used in criti-
ally ill HF patients as a “bridge” to heart transplantation or
s “destination therapy” for those who have failed medical
herapy and are ineligible for heart transplantation. There is
o sex difference in the surgical technique for implanting
hese devices. However, small women have limited options,
ecause devices like implantable left VADs require a min-
mum body surface to fit properly.
The VAD outcome data comparing women and men
emain limited (56,57). One study noted that women were
ore likely than men to require a right VAD after implan-
ation of a left VAD, but there were few women participants
nd pre-VAD implantation data were not analyzed (56). In
nother study in which women had a worse prognosis,
omen were clinically more unstable than men before VAD
mplantation. Survival after VAD correlated best with the
egree of medical severity before VAD implantation and
ot sex (57). The recent Food and Drug Administration
pproval of the HeartMate II (Thoratec Corporation, Pleas-
nton, California) a small continuous flow device, will allow
he implantation of more VADs in women and enable data
nalysis in a more consistent prospective manner, because it
ill be added to the INTERMACS (Interagency Registry
or Mechanically Assisted Circulatory Support) National
eart, Lung, and Blood Institute patient registry for VADs. aeart transplantation. In the U.S. for 2007, women
onated 28% of the available hearts and received 26% of the
earts transplanted. The overall survival after transplanta-
ion on the basis of UNOS (United Network of Organ
haring) data from 1997 to 2004 was slightly worse for
omen (i.e., survival rate female vs. male: 1 year 86% vs.
8%, 3 years 76% vs. 79%, 5 years 68% vs. 72%) (58). The
ost recent data (2007) from the International Society for
eart and Lung Transplantation (59) showed that the sex
f the donor or recipient did not significantly affect 1-year
ortality but that the RR of 5-, 10-, and 15-year mortality was
lightly increased for male recipients who received female
earts (5-year RR: 1.2, 95% CI: 1.05 to 1.37, p  0.0093;
0-year RR: 1.08, 95% CI: 1.01 to 1.17, p  0.0309; 15-year
R: 1.13, 95% CI: 1.01 to 1.25, p 0.0334). With respect to
oronary allograft vasculopathy, the RR within 5 years was
ighest for recipients who received male donor hearts and
owest for female recipients who received female donor
earts (59).
onclusions
pproximately 2.7 million women have HF. Heart failure
ffects women at an older age with better LV systolic
unction, compared with men. Women are more likely to
ave hypertension and valvular disease as the etiology and
ess likely to have CAD. However, CAD is such an
mportant risk factor that a woman with CAD is more likely
o develop HF than a woman with hypertension. Survival
or women with HF is better than for men, and the reason
emains unclear but might in part be related to sex differ-
nces in etiology, with a worse survival in both women and
en with ischemic cardiomyopathy.
Since the landmark HF in women review article by Petrie
t al. (60) in 1999, which was striking mainly because of the
ack of sex-specific data, we have learned more regarding
pidemiology, prognostic testing, and the rare disease
PCM. We continue to know little sex-specific information
egarding therapy. At least 9 multicenter HF studies have
een published since Petrie’s article (i.e., RALES [43], EPHE-
US [44], A-HeFT [47], CHARM [37], ELITE II [Lo-
artan Heart Failure Survival Study] [61], Val-HeFT [38],
OPERNICUS [40], COMPANION [52], and
ARE-HF [53]) and on average included 28% women.
his is an improvement in enrollment compared with the
9% reported by Petrie et al. but still an under-representation
or a disease that has approximately 40% women with
mpaired systolic function and 60% women with preserved
V function (3). Our current HF guidelines are not sex
pecific because of insufficient data, but our review of the
ublished reports raises concern that sex differences might
xist regarding the degree of benefit of any given therapy.
or instance, retrospective analysis revealed a morbidity
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August 4, 2009:491–8 HF in Womenlockers, aldosterone antagonists, or CRT but did not show
he same benefit with ACEI or ICD, despite all studies
aving a paucity of female participants.
What do we need to do to change the future? Since 1986
he National Institutes of Health (NIH) has requested that
omen be included in clinical trials, and in 1993 an NIH
evitalization Act was passed that stipulated that a sufficient
umber of women be included in NIH-sponsored trials to
eport meaningful sex-specific results. Despite the NIH
ttempts, there continues to be a low rate of sex-specific
eporting in cardiovascular trials (62). Although journal
ditors could require sex-specific results, it does not change
he fact that most clinical HF trials were not designed to
ven determine sex differences. Changes need to be made,
ut who should accept this responsibility and how to enforce
t remains controversial.
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